1Departments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA;
2Cystic Fibrosis Foundation, Bethesda, Maryland, USA;
3Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA;
4Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA;
5Department of Medicine, University of Alabama, Birmingham, Alabama, USA; and
6Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA
Correspondence and requests for reprints should be addressed to Pradeep K. Singh, M.D., University of Washington, 1959 NE Pacific Street, Rm J-287, Box 357735, Seattle, WA 98195-7242. Email: [email protected].
A complete list of PROMISE-Micro Study Group members may be found before the beginning of the References.
Supported by Cystic Fibrosis Foundation grants MICRO18K1 (P.K.S.) and Singh19R0 (P.K.S.) and NIH NHLBI grant R01HL148274 (P.K.S.). Additional support was provided by the Cystic Fibrosis Foundation Research Development Programs at University of Washington and Dartmouth (SINGH19R0 and STANTO19R0) and both institutions' NIH P30s (DK117469 and DK089507). The funders had no role in the design, management, data collection, analyses, or interpretation of the data. The views expressed are those of the authors. The content of this manuscript is the responsibility of the authors alone and does not necessarily reflect the views or policies of the study sponsors.
Clinical trial registered with www.clinicaltrials.gov (NCT04038047).
Originally Published in Press as DOI: 10.1164/rccm.202406-1128RL on August 27, 2024
Author disclosures are available with the text of this letter at www.atsjournals.org.
